Sanofi Moves Up In MS With Frexalimab Success
Anti-CD40L Antibody Significantly Reduced Disease Activity
Much of the focus on the French major’s MS pipeline has been on the BTK inhibitor tolebrutinib but promising Phase II data on frexalimab have caught the eye.
